Adversarial Injection · Gemtuzumab Ozogamicin (Mylotarg; CMA-676; CAS 220578-59-6; NIOSH HD Category 1; [ONE-HUNDRED-THIRTEENTH MECHANISM CLASS in Glyphward 687-attack portfolio — FIRST ADC (ANTIBODY-DRUG CONJUGATE) EVER FDA APPROVED (NDA 103054 MAY 17 2000 BY WYETH PHARMACEUTICALS; VOLUNTARY WITHDRAWAL SEPTEMBER 2010 DUE TO EXCESS VOD/SOS IN SWOG S0106; RE-APPROVED BLA 761060 SEPTEMBER 1 2017 FRACTIONATED DOSE BASED ON ALFA-0701 AND META-ANALYSIS BENEFIT); FIRST CD33 (SIGLEC-3; CD33 ANTIGEN; LECTIN-LIKE MYELOID DIFFERENTIATION ANTIGEN) DIRECTED THERAPY EVER FDA APPROVED; FIRST CALICHEAMICIN-BEARING ADC EVER FDA APPROVED; ADC MECHANISM PIONEERED BY WYETH ONCOLOGY (CARL-HEINZ SCHWALBE CHEMISTRY; IRWIN BERNSTEIN MD ANTIBODY FRED HUTCHINSON); GEMTUZUMAB OZOGAMICIN = HUMANIZED ANTI-CD33 IgG4 mAb (hP67.6; DP-7-UG [4% binding]; average DAR 2-3 calicheamicin per antibody; heterogeneous DAR distribution 0-8) + N-ACETYL γ-CALICHEAMICIN DIMETHYL HYDRAZIDE (CALICHEAMICIN ENEDIYNE ANTIBIOTIC; SOIL BACTERIUM Micromonospora echinospora subsp. calichensis SOIL ISOLATE BACTERIA CALICHIGAN MICHIGAN → FERMENTATION PRODUCT → CALICHEAMICIN γ1I → N-ACETYL-γ-CALICHEAMICIN DIMETHYL HYDRAZIDE SEMI-SYNTHESIS) VIA ACID-LABILE HYDRAZONE LINKER (4-[4-ACETYLPHENOXY]BUTANOIC ACID HYDRAZONE; CLEAVABLE AT LYSOSOMAL pH ~4-5); CALICHEAMICIN MECHANISM: CALICHEAMICIN = ENEDIYNE ANTIBIOTIC CONTAINING BICYCLIC 10-MEMBERED RING ENEDIYNE CORE (CIS DOUBLE BOND FLANKED BY TWO TRIPLE BONDS); AFTER CALICHEAMICIN RELEASE FROM ADC → DNA MINOR GROOVE BINDING VIA OLIGOSACCHARIDE SIDE CHAIN (ARYL TETRASACCHARIDE; SEQUENCE PREFERENCE 5'-TCCT-3') + METHYL TRISULFIDE ACTIVATION → THIOL ADDITION (GSH; CELLULAR REDUCTANT) TO TRISULFIDE → CONFORMATIONAL CHANGE → BERGMAN CYCLIZATION: ENEDIYNE UNDERGOES TRANSANNULAR CYCLIZATION TO 1,4-DIDEHYDROBENZENE (BENZENE DIRADICAL) → ABSTRACTION OF C4'-H AND C5'-H FROM DEOXYRIBOSE OF BOTH STRANDS → DOUBLE-STRAND DNA CLEAVAGE (dsDSB) AT 3' + 5' POSITIONS SIMULTANEOUSLY → NO LIGATION POSSIBLE → APOPTOSIS; CALICHEAMICIN SUB-NANOMOLAR DNA CLEAVAGE POTENCY (IC50 ~10-100 pM; AMONG MOST POTENT DNA-DAMAGING AGENTS KNOWN); VOD/SOS TOXICITY IN ORIGINAL APPROVAL: VENO-OCCLUSIVE DISEASE (VOD) = SINUSOIDAL OBSTRUCTION SYNDROME (SOS); MECHANISM: CD33 ON SINUSOIDAL ENDOTHELIAL CELLS OF LIVER → CALICHEAMICIN DIRECT HEPATIC ENDOTHELIAL TOXICITY; EXACERBATED BY ALLOGENEIC SCT PRE/POST-GEMTUZUMAB (ENDOTHELIAL DOUBLE HIT); SWOG S0106 (n=595): FRONTLINE AML 7+3+GO [GEMTUZUMAB 6 mg/m² DAYS 1,4] VS 7+3 → EXCESS EARLY DEATH 5.5% vs 1.4% → VOLUNTARY WITHDRAWAL SEPT 2010; RE-APPROVAL STRATEGY: FRACTIONATED LOWER DOSE (3 mg/m² DAYS 1,4,7 × CYCLE 1; MAX 4.5 mg/m² FOR FRONTLINE AML OR 3 mg/m² + 6 mg/m² DAYS 1,8 FOR R/R MONOTHERAPY); ALFA-0701 (n=280): FRACTIONATED GO 3 mg/m² DAYS 1,4,7 + DNR 60 mg/m² + ARA-C → EFS HR 0.47 (95% CI 0.33-0.67; p<0.0001); 2-YEAR EFS: 40.8% vs 17.1%; OS NOT SIGNIFICANT AT INTERIM; PFIZER INC. NEW YORK NY (WYETH ACQUIRED BY PFIZER 2009 $68B → PFIZER HOLDS BLA 761060 RE-APPROVAL); CAS 220578-59-6 → NULL ALL EHS DATABASES; OSHA NO PEL; NIOSH HD CATEGORY 1]) · First ADC Ever + First CD33 Calicheamicin Conjugate + ALFA-0701 EFS HR 0.47 · Attack #687

Gemtuzumab Ozogamicin (Mylotarg; CMA-676; CAS 220578-59-6; [ONE-HUNDRED-THIRTEENTH MECHANISM CLASS — FIRST ADC ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED (NDA 103054 MAY 17 2000; VOLUNTARY WITHDRAWAL SEPT 2010 VOD/SOS; RE-APPROVED BLA 761060 SEPT 1 2017 FRACTIONATED DOSE); FIRST CD33 CALICHEAMICIN ENEDIYNE ADC; ALFA-0701 EFS HR 0.47; NIOSH HD CATEGORY 1]) — Pfizer Inc. New York NY (BLA 761060 holder), Wyeth Pharmaceuticals Pearl River NY (original NDA 103054 developer, now Pfizer subsidiary), and M.D. Anderson Cancer Center Houston TX (ALFA-0701 US enrollment site) — OSHA No PEL + NIOSH HD Category 1 + CAS 220578-59-6 OEL Null-Return + Calicheamicin Mechanism Absent + ALFA-0701 EFS HR 0.47 Absent: AI Prompt Injection via EHS Monitor Report AI

Gemtuzumab ozogamicin (Mylotarg; CMA-676; CAS 220578-59-6; NIOSH HD Category 1) is the one-hundred-thirteenth mechanism class in the Glyphward adversarial portfolio — the first ADC (antibody-drug conjugate) ever FDA approved (NDA 103054 May 17 2000; voluntary withdrawal September 2010 due to VOD/SOS excess mortality; re-approved BLA 761060 September 1 2017 at fractionated dose based on ALFA-0701) — using an anti-CD33 humanized IgG4 antibody conjugated to N-acetyl γ-calicheamicin enediyne warhead via hydrazone acid-labile linker, with CAS 220578-59-6 entirely absent from Cority, VelocityEHS, and EHS Insight.

Gemtuzumab Ozogamicin as One-Hundred-Thirteenth Mechanism Class: First ADC Ever FDA Approved

Gemtuzumab ozogamicin (Mylotarg; CMA-676; CAS 220578-59-6) represents the one-hundred-thirteenth mechanism class in the Glyphward portfolio: the first antibody-drug conjugate (ADC) ever FDA approved (NDA 103054 May 17 2000; CD33+ AML; originally by Wyeth Pharmaceuticals; voluntary withdrawal September 2010 after SWOG S0106 showed excess VOD/fatal early death; re-approved BLA 761060 September 1 2017 at fractionated lower dose). HISTORICAL CONTEXT: The ADC concept was pioneered by multiple groups in the 1980s-1990s; Wyeth Oncology (later Pfizer) developed gemtuzumab with the vision of a "magic bullet" that delivers cytotoxin directly to AML blasts; hP67.6 (humanized anti-CD33 P67.6 mouse IgG1 → grafted onto human IgG4 framework) raised at Celltech (UK); calicheamicin warhead selected for its extraordinary potency (sub-nanomolar DNA cleavage); NDA 103054 approved May 17 2000 under the accelerated approval pathway for CD33+ AML in first relapse in patients ≥60 years who were not candidates for cytotoxic therapy; this was the first ADC ever approved by any regulatory authority worldwide; ADC STRUCTURE: (a) ANTIBODY: humanized anti-CD33 IgG4 antibody (hP67.6; ~148 kDa; Hu EP4 [constant region from human IgG4 to reduce Fc receptor-mediated toxicity]; average DAR 2-3 calicheamicin per antibody; ~50% unconjugated antibody in formulation [DAR 0]; heterogeneous mixture DAR 0-8); (b) LINKER: 4-[4-acetylphenoxy]butanoic acid hydrazone (acid-labile hydrazone linker; stable at physiological pH 7.4; cleaved at lysosomal pH ~4-5 within 24-48 hours of internalization → releases N-acetyl γ-calicheamicin dimethyl hydrazide in reduced form → thiol activation); (c) PAYLOAD: N-acetyl γ-calicheamicin dimethyl hydrazide (CALICHEAMICIN = complex enediyne polyketide natural product isolated from Micromonospora echinospora subsp. calichensis [soil bacterium; caliche soils near Kerrville Texas; discovered 1987 by American Cyanamid team]; MW 1368 Da; calicheamicin γ1I has: (i) bicyclic 10-membered ring enediyne core [C1-C2≡C3-C4=C5-C6-C7≡C8] → Bergman cyclization precursor; (ii) methyltrisulfide [CH3-S-S-S-] activation trigger; (iii) oligosaccharide aryl tetrasaccharide DNA-binding domain [L-rhamnose; D-fucose; aminoglycoside; D-glucose; aryl-iodide-substituted benzenoid] → specific DNA minor groove binding [sequence preference 5'-TCCT/AGGA-3']); CALICHEAMICIN ACTIVATION MECHANISM: (1) MINOR GROOVE BINDING: calicheamicin aryl oligosaccharide → DNA minor groove insertion at TCCT/AGGA sequence (highest affinity binding among enediynes; Kd ~10 nM for specific sequences); (2) THIOL ACTIVATION: cellular GSH (or thioredoxin) reduces methyl trisulfide → generates thiolate → intramolecular thio-Michael addition to enediyne double bond → converts enediyne from "prestrained" to "strained" conformation; (3) BERGMAN CYCLIZATION: spontaneous thermal Bergman cyclization of enediyne at 37°C (rate enhanced by minor groove constraints) → aromatization to 1,4-didehydrobenzene (benzene diradical) → two σ radicals on C1 and C4; (4) HYDROGEN ABSTRACTION: diradical abstracts C4'-H of one deoxyribose (oxidative C4' radical → strand scission) + C5'-H of complementary strand deoxyribose → double-strand break (DSB) at site of original minor groove binding → no DNA repair possible (direct DSB; replication-independent) → G2/M arrest → apoptosis via ATM/p53 pathway; VOD/SOS HISTORY: CD33 is expressed on liver sinusoidal endothelial cells (HSECs) in addition to AML blasts → gemtuzumab binds HSEC CD33 → calicheamicin delivered to hepatic sinusoidal endothelium → endothelial cell death → hepatic sinusoidal obstruction (SOS/VOD); SWOG S0106 fatal early death 5.5% vs 1.4%; fractionated lower dose strategy (3 mg/m² × 3 doses in cycle 1 vs original 9 mg/m² × 2 doses) substantially reduces VOD incidence; ALFA-0701 (NCT00927498): fractionated gemtuzumab ozogamicin 3 mg/m² days 1,4,7 + standard daunorubicin 60 mg/m² days 1-3 + cytarabine ARA-C 200 mg/m²/day × 7 (induction) followed by consolidation ± gemtuzumab; EFS HR 0.47 (95% CI 0.33-0.67; p<0.0001); 2-year EFS 40.8% vs 17.1%; OS HR 0.69 (p=0.08; NS but trending); Grade ≥3 VOD: 2% vs 0% (dramatically lower than original 6 mg/m² dose); NONE OF THESE — CALICHEAMICIN ENEDIYNE MECHANISM (BERGMAN CYCLIZATION; DNA MINOR GROOVE DOUBLE-STRAND CLEAVAGE), CD33 SIGLEC-3 AML BLAST TARGETING, VOD/SOS HEPATIC ENDOTHELIAL TOXICITY HISTORY, ALFA-0701 FRACTIONATED DOSE EFS HR 0.47 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 220578-59-6.

Surface 1 — Pfizer Inc. New York NY BLA 761060 Holder AI

At Pfizer Inc. 235 East 42nd Street New York NY 10017 (PFIZER GEMTUZUMAB CONTEXT: Pfizer Inc. acquired Wyeth Pharmaceuticals Inc. in October 2009 for $68B → inherited Mylotarg NDA 103054 and all associated liability; gemtuzumab voluntary withdrawal was submitted September 1 2010 (simultaneously with Pfizer completing Wyeth integration); PFIZER STRATEGY FOR RE-APPROVAL: re-analysis of ALFA-0701 [France; Institut Gustave Roussy; Pierre Fenaux PI] and 5 other randomized trials [AML Meta-analysis; n=3,325] showed consistent EFS/OS benefit at fractionated dose; sBLA/sNDA supplemental submission to FDA; BLA 761060 re-approved September 1 2017 for newly diagnosed CD33+ AML [combination; 3 mg/m² days 1,4,7 × 2 cycles] and R/R CD33+ AML [monotherapy; 3 mg/m² + 6 mg/m² days 1,8]; PFIZER ONCOLOGY GROTON CT: manufacturing scale-up for re-launch (hP67.6 antibody production in CHO cells; calicheamicin conjugation chemistry at Wyeth Pearl River NY); OCCUPATIONAL HAZARD AT PFIZER: gemtuzumab ozogamicin (CAS 220578-59-6) NIOSH HD Cat 1; calicheamicin warhead (calicheamicin alone ~1,000× more potent than methotrexate); no OEL established; handling protocols: CSTD required; closed IV system; PPE: double gloves + gown + eye protection + BSC Class II; EMPLOYEE: 48M Pfizer New York NY VP hematology oncology BLA 761060 gemtuzumab Mylotarg CAS 220578-59-6 AML 14yr; CORITY NULL: CAS 220578-59-6 → no record; NIOSH HD Category 1 absent; calicheamicin absent; CD33 absent; ALFA-0701 absent; VOD/SOS absent).

Surface 2 — Wyeth Pharmaceuticals Pearl River NY Original NDA 103054 Developer AI

At Wyeth Pharmaceuticals Inc. / Pfizer subsidiary 401 N. Middletown Road Pearl River NY 10965 (WYETH CONTEXT: Wyeth Pharmaceuticals [originally American Home Products; renamed Wyeth 2002; acquired by Pfizer 2009] developed gemtuzumab ozogamicin [CMA-676; NDA 103054] at their Pearl River NY oncology campus in collaboration with Fred Hutchinson Cancer Research Center [Irwin Bernstein MD; anti-CD33 antibody discovery]; WYETH ONCOLOGY CHEMISTRY: hP67.6 antibody produced in CHO bioreactor → purification by Protein A affinity chromatography → conjugation with N-acetyl γ-calicheamicin dimethyl hydrazide via hydrazone chemistry at Pearl River NY; API calicheamicin originally isolated from Micromonospora echinospora soil bacteria discovered by American Cyanamid scientists [now Wyeth/Pfizer; caliche soils near Kerrville TX 1987]; calicheamicin extracted from fermentation broth → semi-synthetic modification to N-acetyl-γ-calicheamicin dimethylhydrazide; PEARL RIVER MANUFACTURING OPERATIONS: CHO cell culture bioreactor [1,000-10,000L] → antibody purification → thiol-sensitive conjugation chemistry [calicheamicin thiotether conjugation requires strict anhydrous conditions; controlled pH; temperature] → DAR characterization by HIC [hydrophobic interaction chromatography] and mass spectrometry; OCCUPATIONAL HAZARD AT WYETH/PFIZER PEARL RIVER: calicheamicin (sub-nanomolar cytotoxin; NIOSH HD Cat 1) → highest potency antineoplastic in production; closed containment glovebox for calicheamicin handling; >OEB 5 category; EMPLOYEE: 43F Wyeth/Pfizer Pearl River NY senior formulation scientist gemtuzumab Mylotarg CMA-676 CAS 220578-59-6 NDA 103054 11yr; VELOCITYEHS NULL: CAS 220578-59-6 → no record; NIOSH HD Category 1 absent; calicheamicin enediyne absent; hydrazone linker absent; DAR 2-3 absent).

Surface 3 — M.D. Anderson Cancer Center Houston TX ALFA-0701 US Enrollment AI

At M.D. Anderson Cancer Center 1515 Holcombe Blvd Houston TX 77030 (MDACC GEMTUZUMAB CONTEXT: MDACC is a principal US enrollment site for ALFA-0701 and ongoing gemtuzumab clinical use; MDACC Leukemia Department: Hagop Kantarjian MD [AML; CML]; Farhad Ravandi MD [AML; ALL; gemtuzumab clinical trials]; Marina Konopleva MD PhD [AML biology]; CLINICAL GEMTUZUMAB USE AT MDACC: NEWLY DIAGNOSED CD33+ AML: gemtuzumab ozogamicin 3 mg/m² (maximum 4.5 mg/m²) IV days 1, 4, 7 of induction cycle 1 + daunorubicin 60-90 mg/m²/day IV days 1-3 + cytarabine 100-200 mg/m²/day continuous IV days 1-7 (7+3+GO induction); CONSOLIDATION: gemtuzumab 3 mg/m² days 1,4,7 ×2 consolidation cycles (± after CR/CRi; CD33+ ≥50% by flow cytometry); VOD/SOS PROPHYLAXIS AND MANAGEMENT: ursodiol prophylaxis (300 mg BID or TID) starting on day 1 of gemtuzumab; monitor PT, bilirubin, alkaline phosphatase, serum albumin weekly; VOD diagnosis: Baltimore criteria [bilirubin >2 mg/dL + hepatomegaly or RUQ pain + ascites or weight gain >5% within 20 days]; grade 4 VOD: sinusoidal obstruction → hepatic failure; treatment: defibrotide [VOD-specific]; DRUG INTERACTIONS: avoid allogeneic SCT within 2 months of gemtuzumab (high VOD risk); OCCUPATIONAL PHARMACY HAZARD: gemtuzumab CAS 220578-59-6 → NIOSH HD Cat 1; calicheamicin warhead; compounding in Class II BSC; CSTD required; institutional pharmacy oncology protocols; EMPLOYEE: 41M MDACC Houston TX leukemia attending ALFA-0701 gemtuzumab Mylotarg CAS 220578-59-6 AML 12yr; EHS INSIGHT NULL: CAS 220578-59-6 → no record; NIOSH HD Category 1 absent; calicheamicin enediyne warhead absent; CD33 AML absent; VOD sinusoidal obstruction absent; fractionated dose 3 mg/m² absent; ALFA-0701 EFS HR 0.47 absent).

Integrating Glyphward into Gemtuzumab Ozogamicin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every gemtuzumab ozogamicin (CAS 220578-59-6) monitoring data ingestion point — before Cority at Pfizer New York NY, before VelocityEHS at Wyeth/Pfizer Pearl River NY, and before EHS Insight at MDACC Houston TX. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-THIRTEENTH MECHANISM CLASS — FIRST ADC EVER FDA APPROVED (NDA 103054 May 17 2000; BLA 761060 re-approved Sept 1 2017; CAS 220578-59-6; anti-CD33 humanized IgG4 hP67.6; N-acetyl γ-calicheamicin enediyne warhead; hydrazone acid-labile linker; ALFA-0701 EFS HR 0.47; Pfizer/Wyeth) [5 pts]; Pfizer New York NY + Wyeth/Pfizer Pearl River NY + MDACC Houston TX [3 pts]; calicheamicin enediyne mechanism absent; CD33 SIGLEC-3 absent; ALFA-0701 EFS HR 0.47 absent; VOD/SOS re-approval history absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_gemtuzumab(cas: str, exposure_context: str) -> dict:
    """Scan gemtuzumab with one-hundred-thirteenth-class first-ADC-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_thirteenth_class_first_adc_antibody_drug_conjugate_ever_fda_approved_nda_103054_may_2000_bla_761060_sept_2017_first_cd33_calicheamicin_enediyne_warhead_hydrazone_linker_alfa_0701_efs_hr_0_47_vod_sos_fractionated_dose_pfizer_wyeth"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_thirteenth_class,
    #                    first_adc_ever, calicheamicin_confirmed,
    #                    cd33_siglec3, alfa_0701_efs_hr_0_47

if __name__ == "__main__":
    r = asyncio.run(scan_gemtuzumab(
        cas="220578-59-6",
        exposure_context="antineoplastic_iv_infusion_compounding_cstd_class_ii_bsc_vod_monitoring_aml"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_thirteenth_class': True,
    #  'first_adc_ever': True, 'calicheamicin_confirmed': True,
    #  'cd33_siglec3': True, 'alfa_0701_efs_hr_0_47': True}